New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
Nagashree Seetharamu, Isabel R Preeshagul, Kevin M Sullivan Monter Cancer Center, Hofstra-Northwell Health School of Medicine, Lake Success, NY, USA Abstract: The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies....
Guardado en:
Autores principales: | Seetharamu N, Preeshagul IR, Sullivan KM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8a0a5dfc63c14e2b808511bcd61aa5dd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Wolfram Samlowski, et al.
Publicado: (2021) -
The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
por: Nikolai A. Ognerubov, et al.
Publicado: (2021) -
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
por: Zoe Apalla, et al.
Publicado: (2021) -
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Anwen Xiong, et al.
Publicado: (2021) -
Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
por: Galina B. Statsenko, et al.
Publicado: (2020)